Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.
   Google Scholar   
Citation:
J. Clin. Oncol. vol 29 (15s) abstr 3607
Meeting Instance:
ASCO 2011
Year:
2011
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Parents:
None
Children:
282   477  
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                             
Primary Study
NCCTG-N0147
Secondary Studies:
Phases:
3
Keywords: